The efficacy of NK-1R antagonists were also confirmed in the study by Rapoport et al43 who recruited patients with different tumor types, including breast cancer, lung cancer, colon cancer, and ovarian cancer. This evidence concerns the gene TACR1 and lung carcinoma.